SCHEMBL4977894

SCHEMBL4977894

COc1cc(NC(=O)Cn2cnc3cccc(C(C)=O)c32)cc(OC)c1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.56
POLB P06746 2/20 0.52
ALDH1A1 P00352 4/20 0.46
ACHE P22303 1/20 0.46
BACE1 P56817 1/20 0.46
USP2 O75604 2/20 0.45
HTT P42858 2/20 0.45
HPGD P15428 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
GFER P55789 2/20 0.45
KDM4E B2RXH2 2/20 0.45
TP53 P04637 1/20 0.45
LMNA P02545 1/20 0.45
HSD17B10 Q99714 1/20 0.45
THRB P10828 1/20 0.45
GAA P10253 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4973402 0.88 TP53 (0.50) MAPTPOLBALDH1A1HTTMEN1
SCHEMBL4979239 0.85 MAPT (0.55) MAPTPOLBALDH1A1ACHEBACE1
SCHEMBL3045466 0.83 MAPT (0.54) MAPTPOLBALDH1A1ACHEBACE1
SCHEMBL4974004 0.81 RXFP1 (0.47) MAPTPOLBKDM4ETP53GAA
SCHEMBL4975792 0.80 POLB (0.54) MAPTPOLBALDH1A1HTTMEN1
SCHEMBL4453735 0.79 POLB (0.47) MAPTPOLBALDH1A1ACHEBACE1
SCHEMBL4973246 0.79 SMN1; SMN2 (0.66) MAPTPOLBALDH1A1HTTMEN1
SCHEMBL3043481 0.79 LMNA (0.50) MAPTPOLBALDH1A1USP2HTT
SCHEMBL4972906 0.78 RXFP1 (0.47) MAPTPOLBACHEUSP2HTT
SCHEMBL4975311 0.78 POLB (0.46) MAPTPOLBALDH1A1ACHEBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080015222-A1 New Heterocyclic Amides ASTRAZENECA AB (SE) 2008-01-17 US claimed
EP-1797067-A1 NEW HETEROCYCLIC AMIDES AstraZeneca AB (SE) 2007-06-20 EP claimed
WO-2006033620-A1 NEW HETEROCYCLIC AMIDES ASTRAZENECA AB (SE) 2006-03-30 WO claimed
US-20080015222-A1 New Heterocyclic Amides ASTRAZENECA AB (SE) 2008-01-17 US disclosed
EP-1797067-A1 NEW HETEROCYCLIC AMIDES AstraZeneca AB (SE) 2007-06-20 EP disclosed
WO-2006033620-A1 NEW HETEROCYCLIC AMIDES ASTRAZENECA AB (SE) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015222-A1 New Heterocyclic Amides AADAC, AVPR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MAPT 441/4885POLB 2972/4885ALDH1A1 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.